Equity Overview
Price & Market Data
Price: $0.987
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $22,924,600
Volume: 0
Performance Metrics
1 Week: -6.89%
1 Month: -8.62%
3 Months: -9.45%
6 Months: -7.76%
1 Year: -30.50%
YTD: -17.75%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.